

**This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.**

**The data included in this report reflect the results of a systematic search and review of data on a range of indicators reflecting the extent of services provided to people who inject drugs.**

**These data have been searched, reviewed and extracted according to decision rules developed by the Reference Group.**

**Some data have been adjusted to facilitate estimates of standard indicators across countries.**

**Details of the process for searching, grading and including data, along with their interpretation, are detailed in:**

Mathers B, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick R, et al. HIV prevention, treatment and care for people who inject drugs: A systematic review of global, regional and national coverage. *The Lancet* 2010. DOI:10.1016/S0140-6736(10)60232-2.

**For more information on the Reference Group, please go to: [www.IDURefGroup.Com](http://www.IDURefGroup.Com)**

Section	Page
Estimated number of people who inject drugs and number of injectors who are living with HIV	4
<b>1. Needle and syringe programs (NSPs)</b>	<b>5</b>
NSP 1: Availability of NSPs	
NSP 2: Number of NSP sites	
NSP 3: Number of pharmacy sites where needles and syringes are available for purchase	
NSP 4: Total number of sites where needles and syringes are available	
NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period	
NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period	
NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period	
<b>2. Opioid substitution programs (OST)</b>	<b>10</b>
OST 1: Availability of opioid substitution treatment (OST)	
OST 2: Availability of methadone maintenance treatment (MMT)	
OST 3: Availability of buprenorphine maintenance treatment (BMT)	
OST 4: Availability of other forms of agonist OST	
OST 5: Dose and duration of MMT	
OST 6: Dose and duration of BMT	
OST 7: Total number of all sites providing OST	
OST 8: Number of sites providing MMT	
OST 9: Number of sites providing BMT	
OST 10: Number of sites providing other forms of agonist OST	
OST 11: Number of all clients in any OST at a single point in time	
OST 12: Number of all clients in MMT at a single point in time	
OST 13: Number of all clients in BMT at a single point in time	
OST 14: Number of all clients in other forms of OST at a single point in time	
OST 15: Number of IDUs in any OST at a single point in time	
OST 16: Number of IDUs in MMT at a single point in time	
OST 17: Number of IDUs in BMT at a single point in time	
OST 18: Number of IDUs in other forms of OST at a single point in time	
OST 19: Number of all clients receiving any OST in a 12 month period	
OST 20: Number of all clients receiving MMT in a 12 month period	
OST 21: Number of all clients receiving BMT in a 12 month period	
OST 22: Number of all clients receiving other forms of OST in a 12 month period	
OST 23: Number of IDUs receiving any OST in a 12 month period	
OST 24: Number of IDUs receiving MMT in a 12 month period	

Section	Page
OST 25: Number of IDUs receiving BMT in a 12 month period	
OST 26: Number of IDUs receiving other forms of OST in a 12 month period	
<b>3. Other Drug Treatment (ODT)</b>	<b>23</b>
<hr/>	
ODT 1: Detoxification	
ODT 1.1: Number of sites providing detoxification	
ODT 1.2: Number of IDUs receiving detoxification	
ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time	
ODT 2: Residential Rehabilitation	
ODT 2.1: Number of sites providing residential rehabilitation	
ODT 2.2: Number of IDUs in residential rehabilitation	
ODT 2.3: Number of all clients in residential rehabilitation	
ODT 3: Outpatient psychosocial support, counselling and psychotherapy	
ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy	
ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment	
ODT 4: Peer-based support groups	
ODT 4.1: Number of sites providing peer-based support groups	
ODT 4.2: Number of IDUs in peer-based support groups	
ODT 4.3: Number of all clients in peer-based support groups	
ODT 5: Drug treatment (treatment type not specified)	
ODT 5.1: Number of sites providing unspecified drug treatment	
ODT 5.2: Number of IDUs receiving unspecified drug treatment	
ODT 5.3: Number of all clients receiving unspecified drug treatment	
ODT 6: Drug treatment in prisons	
ODT 6.1: Number of drug treatment sites located in prisons	
ODT 6.2: Number of IDUs receiving drug treatment in prisons	
ODT 6.3: Number of all clients receiving drug treatment in prisons	
ODT 7: Compulsory drug treatment	
ODT 7.1: Number of compulsory detention sites for drug use	
ODT 7.2: Number of IDUs in compulsory detention sites for drug use	
ODT 7.3: Number of all drug users in compulsory detention sites for drug use	
<b>4. HIV testing and counselling (T&amp;C)</b>	<b>39</b>
<hr/>	
T&C 1: Availability of HIV T&C	
T&C 2: Number of sites providing HIV T&C that specifically targets IDUs	

Section	Page
T&C 3: Number of T&C sites providing HIV T& to the general population and also accessible to IDUs	
T&C 4: Number of individual IDUs who were tested for HIV in a 12 month period	
T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result	
<b>5. Anti-retro-viral (ARV) treatment</b>	<b>42</b>
<hr/>	
ARV 1: Number of sites providing ARV treatment	
ARV 2: Number of IDUs receiving ARVs at a single point in time	
ARV 3: Restrictions on IDUs' access to ARVs	
<b>6. Condoms</b>	<b>45</b>
<hr/>	
Condoms 1: Availability of condom programs targeting IDUs	
Condoms 2: Number of sites distributing condoms to IDUs	
Condoms 3: Number of individual IDUs receiving condoms	
Condoms 4: Number of condoms distributed to IDUs	

## Maldives (South Asia)

### Estimated number of people who inject drugs and number of injectors who are living with HIV

Estimated prevalence of IDU among general population aged 15-64 years (%)	Low	Mid	High
	NK	NK	NK
Year of IDU prevalence estimate			
Reference for IDU prevalence estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
Estimated prevalence of HIV among people who inject (%)	Low	Mid	High
	NK	NK	NK
Year of HIV prevalence among IDU estimate			
Reference for HIV prevalence among IDU estimate	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.		
General population 15-64 years of age in 2008	203 403 (source: UN Population Division, 2009)		
Estimated IDU population in 2008	Low	Mid	High
	NK	NK	NK
Estimated number of IDUs living with HIV in 2008	Low	Mid	High
	NK	NK	NK

## 1. Needle and syringe programs (NSPs)

### NSP 1: Availability of NSPs

Are NSPs available?	No
Comments	
Most recent year of documentation	2007
Reference	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime
When were NSPs first introduced?	
Reference	
Are needles and syringes available for purchase from pharmacies?	
Most recent year of documentation	
Reference	

### NSP 2: Number of NSP sites

Data reported	0 sites		
Year of reported data	2007		
Reference	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.  Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	197 301 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of NSP sites per 1000 IDUs	Low	Mid	High
	0	0	0

**NSP 3: Number of pharmacy sites where needles and syringes are available for purchase**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of pharmacy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

**NSP 4: Total number of sites where needles and syringes are available**

Total number (NSP sites + Pharmacy sites)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
INDICATOR: Total number of sites per 1000 IDUs	Low	Mid	High

## NSP 5: Number of individual IDUs in contact with NSPs in a 12 month period

Data reported	0 clients		
Year of reported data	2007		
Reference	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	197 301 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in contact with NSPs in a 12 month period	Low	Mid	High
	0	0	0

## NSP 6: Number of NSP occasions of service (client contacts) in a 12 month period

Data reported	0 occasions of service		
Year of reported data	2007		
Reference	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	197 301 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of NSP occasions of service (client contacts) in a 12 month period per IDU	Low	Mid	High
	0	0	0

NSP 7: Number of needles and syringes distributed by NSPs in a 12 month period

<b>Data reported</b>	0 syringes and needles distributed		
<b>Year of reported data</b>	2007		
<b>Reference</b>	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime.  World Health Organisation (2009). Universal Access Unpublished Data.;		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	197 301 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Total number of needles/syringes distributed in a 12 month period per IDU</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

**NSP: All documents reviewed**

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU Harm Reduction in SAARC countries Prevention of transmission of HIV among drug users in SAARC countries. UNODC.

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

**2. Opioid substitution treatment (OST)****OST 1: Availability of opioid substitution treatment (OST)**

Are any forms of agonist OST available?	Yes
Comments	
Most recent year of documentation	2008
Reference	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).
When was agonist OST first available?	
Reference	

**OST 2: Availability of methadone maintenance treatment (MMT)**

Is MMT available?	Yes
Comments	
Most recent year of documentation	2008
Reference	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).
When was MMT first available?	
Reference	

**OST 3: Availability of buprenorphine maintenance treatment (BMT)**

Is BMT available?	
Comments	
Most recent year of documentation	
Reference	
When was BMT first available?	
Reference	

**OST 4: Availability of other forms of agonist OST**

Are other forms of OST available?	
Comments	
Most recent year of documentation	
Reference	
When were other forms of OST first available?	
Reference	

## OST 5: Dose and duration of MMT

Average/standard maintenance dose of MMT	
Comments	
Year	
Reference	
Average/standard duration of MMT (range)	
Comments	
Year	
Reference	

## OST 6: Dose and duration of BMT

Average/standard maintenance dose of BMT	
Comments	
Year	
Reference	
Average/standard duration of BMT (range)	
Comments	
Year	
Reference	

## OST 7: Total number of all sites providing OST

Data reported	1 MMT site		
Year of reported data	2008		
Reference	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).  WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	203 403 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of OST sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## OST 8: Number of sites providing MMT

Data reported	1 MMT site		
Year of reported data	2008		
Reference	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	1		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	203 403 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of MMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

## OST 9: Number of sites providing BMT

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of BMT sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

**OST 10: Number of sites providing other forms of agonist OST**

<b>Data reported</b>			
<b>Year of reported data</b>			
<b>Reference</b>			
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>			
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
<b>Reference</b>			
<b>General population 15-64 years of age at year of reported data</b>			
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Number of sites providing other forms of OST per 1000 IDUs</b>	Low	Mid	High
	NK	NK	NK

**OST 11: Number of all clients in any OST at a single point in time**

<b>Data reported</b>	OST available but number of clients on OST not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST at census date : 100 IDUs</b>	Low	Mid	High
	NK	NK	NK

**OST 12: Number of all clients in MMT at a single point in time**

<b>Data reported</b>	MMT available but number of clients not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT at census date : 100 IDUs</b>	Low	Mid	High
	NK	NK	NK

**OST 13: Number of all clients in BMT at a single point in time**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

**OST 14: Number of all clients in other forms of OST at a single point in time**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST at census date : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 15: Number of IDUs in any OST at a single point in time

<b>Data reported</b>	OST available but number of IDU on OST not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in OST at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

## OST 16: Number of IDUs in MMT at a single point in time

<b>Data reported</b>	MMT available but number of IDUs not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in MMT at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

**OST 17: Number of IDUs in BMT at a single point in time**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in BMT at a single point in time	Low	Mid	High
	NK	NK	NK

**OST 18: Number of IDUs in other forms of OST at a single point in time**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

**OST 19: Number of all clients receiving any OST in a 12 month period**

<b>Data reported</b>	14 clients in MMT		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
<b>Adjustments</b>	Assumed total number of clients enrolled in OST throughout 2008		
<b>Final/Adjusted data (to be used as indicator numerator)</b>	14		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on any OST in a 12 month period : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

**OST 20: Number of all clients receiving MMT in a 12 month period**

<b>Data reported</b>	14 clients in MMT		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
<b>Adjustments</b>	Assumed total number of clients enrolled in MMT throughout 2008		
<b>Final/Adjusted data (to be used as indicator numerator)</b>	14		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on MMT in a 12 month period : 100 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

**OST 21: Number of all clients receiving BMT in a 12 month period**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on BMT in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

**OST 22: Number of all clients receiving other forms of OST in a 12 month period**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of total number of all clients (including IDUs and non-IDUs) on other forms of OST in a 12 month period : 100 IDUs	Low	Mid	High
	NK	NK	NK

## OST 23: Number of IDUs receiving any OST in a 12 month period

Data reported	OST available but number of IDU on OST not known		
Year of reported data	2008		
Reference	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	203 403 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving OST in a 12 month period	Low	Mid	High
	NK	NK	NK

## OST 24: Number of IDUs receiving MMT in a 12 month period

Data reported	MMT available but number of IDUs not known		
Year of reported data	2008		
Reference	Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	203 403 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving MMT in a 12 month period	Low	Mid	High
	NK	NK	NK

**OST 25: Number of IDUs receiving BMT in a 12 month period**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving BMT in a 12 month period	Low	Mid	High
	NK	NK	NK

**OST 26: Number of IDUs receiving other forms of OST in a 12 month period**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving other forms of OST at a single point in time	Low	Mid	High
	NK	NK	NK

**OST: All documents reviewed**

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU Harm Reduction in SAARC countries Prevention of transmission of HIV among drug users in SAARC countries. UNODC.

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime

Sharma, M., E. Oppenheimer, et al. (2009). "A situation update on HIV epidemics among people who inject drugs and national responses in South-East Asia Region." AIDS (Accepted for publication).

### 3. Other drug treatment (ODT)

#### ODT 1 - Detoxification

##### ODT 1.1: Number of sites providing detoxification

Is detoxification available?	No		
Number of sites - data reported	0 sites		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	209 320 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of detoxification sites per 1000 IDUs	Low	Mid	High
	0	0	0

**ODT 1.2: Number of IDUs receiving detoxification**

<b>Data reported</b>	0 clients		
<b>Year of reported data</b>	2009		
<b>Reference</b>	World Health Organisation (2009). Global health ATLAS data.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	0		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	209 320 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in detoxification in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0
<b>INDICATOR: Percentage of IDUs in detoxification at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	0	0	0

**ODT 1.3: Number of all clients receiving detoxification in a 12 month period and/or at a single point in time**

<b>Data reported</b>	0 clients		
<b>Year of reported data</b>	2009		
<b>Reference</b>	World Health Organisation (2009). Global health ATLAS data.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	0		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	0		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	209 320 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of number of all clients in detoxification in a 12 month period : number of IDUs</b>	Low	Mid	High
	0	0	0
<b>INDICATOR: Ratio of number of all clients in detoxification at a single point in time : number of IDUs</b>	Low	Mid	High
	0	0	0

**ODT 2 - Residential rehabilitation**

**ODT 2.1: Number of sites providing residential rehabilitation**

Is residential rehabilitation present?			
Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of residential rehabilitation sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

**ODT 2.2: Number of IDUs in residential rehabilitation**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in residential rehabilitation at a single point in time	Low	Mid	High
	NK	NK	NK

**ODT 2.3: Number of all clients in residential rehabilitation**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in residential rehabilitation at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

ODT 3 - Outpatient psychosocial support, counselling and psychotherapy

ODT 3.1: Number of sites providing outpatient psychosocial support, counselling or psychotherapy treatment

Is outpatient psychosocial support, counselling or psychotherapy present?	Yes		
Number of sites - data reported	Psychotherapy, counselling or psychosocial support present but number not known		
Year of reported data	2009		
Reference	World Health Organisation (2009). Global health ATLAS data.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	209 320 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of outpatient psychosocial support, counselling or psychotherapy sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

**ODT 3.2: Number of IDUs receiving outpatient psychosocial support, counselling or psychotherapy treatment**

<b>Data reported</b>	Psychotherapy, counselling or psychosocial support present but number not known		
<b>Year of reported data</b>	2009		
<b>Reference</b>	World Health Organisation (2009). Global health ATLAS data.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	209 320 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs in outpatient psychosocial support, counselling or psychotherapy in a 12 month period</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Percentage of IDUs receiving outpatient psychosocial support, counselling or psychotherapy at a single point in time</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

**ODT 3.3: Number of all clients receiving outpatient psychosocial support, counselling or psychotherapy treatment**

<b>Data reported</b>	Psychotherapy, counselling or psychosocial support present but number not known		
<b>Year of reported data</b>	2009		
<b>Reference</b>	World Health Organisation (2009). Global health ATLAS data.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	209 320 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy in a 12 month period : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in outpatient psychosocial support, counselling or psychotherapy at a single point in time : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

ODT 4 - Peer-based support groups

ODT 4.1: Number of peer-based support groups sites

Are Peer-based support groups present?	Yes		
Number of sites - data reported	4 NA meetings per week		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments	Assumed each meeting per week occurs at a separate location		
Final/Adjusted data (to be used as indicator numerator)	4		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	203 403 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of peer-based support groups sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 4.2: Number of IDUs in peer-based support groups

Data reported	Narcotics Anonymours present but number not known		
Year of reported data	2008		
Reference	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)	NK		
Final/Adjusted data for single point in time (to be used as indicator numerator)	NK		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	203 403 null		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in peer-based support groups at a single point in time	Low	Mid	High
	NK	NK	NK

**ODT 4.3: Number of all clients in peer-based support groups**

<b>Data reported</b>	Narcotics Anonymous present but number not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	Narcotics Anonymous World Services (2009). Quadrennial report for non-governmental organizations - July 2009.		
<b>Adjustments</b>			
<b>Final/Adjusted data for 12 month period (to be used as indicator numerator)</b>	NK		
<b>Final/Adjusted data for single point in time (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 null		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in peer-based support groups in a 12 month period : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Ratio of number of all drug users in peer-based support groups at a single point in time : number of IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	null	null

**ODT 5 - Drug treatment (treatment type not specified)**

**ODT 5.1: Number of drug treatment sites (treatment type not specified)**

Type of drug treatment available			
Number of sites - data reported	treatment centres (or 'DACs' as they are called) + About 450 De-addiction centres are being run by the NGOs		
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of drug treatment sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

**ODT 5.2: Number of IDUs in drug treatment (treatment type not specified)**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in drug treatment not specified/drug treatment combined at a single point in time	Low	Mid	High
	NK	NK	NK

**ODT 5.3: Number of all clients in drug treatment (treatment type not specified)**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of number of all drug users in drug treatment not specified/drug treatment combined at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	NK

**ODT 6 - Drug treatment in prisons**

**ODT 6.1: Number of prison drug treatment sites**

Type of drug treatment in prisons?	
Number of sites - data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data	

**ODT 6.2: Number of IDUs in drug treatment in prisons**

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

**ODT 6.3: Number of all clients in drug treatment in prisons**

Data reported	
Year of reported data	
Reference	
Adjustments	
Final/Adjusted data for 12 month period	
Final/Adjusted data for single point in time	

ODT 7 - Compulsory detention as response to drug use

ODT 7.1: Number of compulsory detention sites for drug use

Number of sites - data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of compulsory detention sites for drug use per 1000 IDUs	Low	Mid	High
	NK	NK	NK

ODT 7.2: Number of IDUs in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings in a 12 month period	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs in compulsory detention in closed settings at a single point in time	Low	Mid	High
	NK	NK	NK

ODT 7.3: Number of all drug users in compulsory detention sites for drug use

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data for 12 month period (to be used as indicator numerator)			
Final/Adjusted data for single point in time (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings in a 12 month period : number of IDUs	Low	Mid	High
	NK	NK	NK
INDICATOR: Ratio of all drug users in compulsory detention in closed settings at a single point in time : number of IDUs	Low	Mid	High
	NK	NK	

**ODT: All documents reviewed**

World Health Organisation (2009). Global health ATLAS data.

## 4. HIV testing and counselling (T&C)

### T&C 1: Availability of HIV T&C

Is T&C available?	Yes
Most recent year of data	2007
Reference	See references for other VCT indicators

### T&C 2: Number of sites providing HIV T&C specifically targeting IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of targeted T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

### T&C 3: Number of sites providing HIV T&C sites to the general population and also accessible to IDUs

Data reported	3 sites		
Year of reported data	2007		
Reference	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU Harm Reduction in SAARC countries Prevention of transmission of HIV among drug users in SAARC countries. UNODC.		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	3		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	197 301 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of all T&C sites per 1000 IDUs	Low	Mid	High
	NK	NK	NK

**T&C 4: Number of Individual IDUs who were tested for HIV in 12 month period**

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of individual IDUs accessing T&Cs in a 12 month period	Low	Mid	High
	NK	NK	NK

**T&C 5: Percentage of IDUs who were tested for HIV in a 12 month period and who know the result**

Year of reported data	
Reference	
Data reported for both male and female IDUs	
Adjustments	
Final/Adjusted data	
Data reported for male IDUs	
Adjustments	
Final/Adjusted data	
Data reported for female IDUs	
Adjustments	
Final/Adjusted data	

**T&C: All documents reviewed**

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU Harm Reduction in SAARC countries Prevention of transmission of HIV among drug users in SAARC countries. UNODC.

**5. Anti-retro-viral (ARV) treatment****ARV 1: Number of sites providing ARV treatment**

<b>Data reported</b>	1 site		
<b>Year of reported data</b>	2008		
<b>Reference</b>	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	1		
<b>IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>HIV among IDU prevalence estimate (%)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level HIV among IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>Estimated number of HIV positive IDUs at year of reported data (to be used as indicator)</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Number of ARV treatment sites per 1000 IDUs</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK
<b>INDICATOR: Number of ARV treatment sites per 1000 IDUs living with HIV</b>	<b>Low</b>	<b>Mid</b>	<b>High</b>
	NK	NK	NK

**ARV 2: Number of IDUs receiving ARVs at a single point in time**

<b>Data reported</b>	Number of IDUs on ART not known		
<b>Year of reported data</b>	2008		
<b>Reference</b>	WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.		
<b>Adjustments</b>			
<b>Final/Adjusted data (to be used as indicator numerator)</b>	NK		
<b>IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>General population 15-64 years of age at year of reported data</b>	203 403 (source: UN Population Division, 2009)		
<b>Estimated number of IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>HIV among IDU prevalence estimate (%)</b>	Low	Mid	High
	NK	NK	NK
<b>Reference</b>	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." The Lancet 372(9651): 1733-1745.  Estimate of country level HIV among IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
<b>Estimated number of HIV positive IDUs at year of reported data (to be used as indicator denominator)</b>	Low	Mid	High
	NK	NK	NK
<b>INDICATOR: Ratio of IDUs on ART: 100 IDUs living with HIV</b>	Low	Mid	High
	NK	NK	NK

**ARV 3: Restrictions on IDUs' access to ARVs**

<b>Do restrictions exist which limit IDUs' access to ARV treatment?</b>	
<b>Year of reported data</b>	
<b>Reference</b>	

**ARV: All documents reviewed**

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime

WHO, UNAIDS., et al. (2009). Towards universal access: Scaling up priority HIV/AIDS interventions in the health sector - progress report 2009. Geneva, WHO.

## 6. Condoms

### Condoms 1: Availability of condom programs targeting IDUs

Are condom programs targeting IDUs available?	No
Comments	
Year	2007
Reference	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime

### Condoms 2: Number of sites distributing condoms to IDUs

Data reported	No sites providing Condoms specifically to IDUs		
Year of reported data	2007		
Reference	Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime		
Adjustments			
Final/Adjusted data (to be used as indicator numerator)	0		
IDU prevalence estimate (%)	Low	Mid	High
	NK	NK	NK
Reference	Mathers, B., L. Degenhardt, et al. (2008). "Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review." <i>The Lancet</i> 372(9651): 1733-1745.  Estimate of country level IDU prevalence not reported but for the purpose of this review this was estimated to be the population-weighted regional prevalence as reported in Mathers et al 2008.		
General population 15-64 years of age at year of reported data	197 301 (source: UN Population Division, 2009)		
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Number of condom distribution sites targeting IDU per 1000 IDUs	Low	Mid	High
	0	0	0

## Condoms 3: Number of individual IDUs receiving condoms

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Percentage of IDUs receiving condoms in a 12 month period	Low	Mid	High
	NK	NK	NK

## Condoms 4: Number of condoms distributed to IDUs

Data reported			
Year of reported data			
Reference			
Adjustments			
Final/Adjusted data (to be used as indicator numerator)			
IDU prevalence estimate (%)	Low	Mid	High
Reference			
General population 15-64 years of age at year of reported data			
Estimated number of IDUs at year of reported data (to be used as indicator denominator)	Low	Mid	High
	NK	NK	NK
INDICATOR: Total number of condoms distributed per 12 month period per IDU	Low	Mid	High
	NK	NK	NK

**Condoms: All documents reviewed**

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU Harm Reduction in SAARC countries Prevention of transmission of HIV among drug users in SAARC countries. UNODC.

Lawyers Collective HIV/AIDS Unit (2007). Legal and policy concerns related to IDU harm reduction in SAARC countries. Regional Office for South Asia, United Nations Office on Drugs and Crime